NASDAQ:RLAY Relay Therapeutics Q4 2025 Earnings Report $19.18 -0.73 (-3.67%) Closing price 04:00 PM EasternExtended Trading$19.84 +0.66 (+3.42%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Relay Therapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.38Beat/MissBeat by +$0.06One Year Ago EPSN/ARelay Therapeutics Revenue ResultsActual Revenue$7.00 millionExpected Revenue$4.34 millionBeat/MissBeat by +$2.66 millionYoY Revenue GrowthN/ARelay Therapeutics Announcement DetailsQuarterQ4 2025Date2/26/2026TimeAfter Market ClosesConference Call DateThursday, February 26, 2026Conference Call Time4:00PM ETUpcoming EarningsRelay Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Relay Therapeutics Earnings HeadlinesRelay Therapeutics (NASDAQ:RLAY) Research Coverage Started at Canaccord Genuity GroupJuly 19 at 1:43 AM | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Buy" from BrokeragesJuly 15, 2026 | americanbankingnews.comNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried to acquire it outright for $40 billion - the White House blocked the deal on national security grounds. So NVIDIA settled for a 20-year supply deal instead. Its architecture delivers '2-3x performance per watt' by NVIDIA's own admission, and its data-center royalties more than doubled last quarter. Analyst Dylan Jovine - who called Palantir at $7.38 and Rocket Lab at $3.80 - has named it his number-one pick ahead of its July 29th earnings report.July 20 at 1:00 AM | Behind the Markets (Ad)Sanjiv Patel Sells 48,199 Shares of Relay Therapeutics (NASDAQ:RLAY) StockJuly 10, 2026 | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Coverage Initiated by Analysts at JPMorgan Chase & Co.July 9, 2026 | americanbankingnews.comRelay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past YearJune 29, 2026 | fool.comSee More Relay Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email. Email Address About Relay TherapeuticsRelay Therapeutics (NASDAQ:RLAY) is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins. The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening. This approach enables Relay to explore conformational changes in proteins that have historically been difficult to target, opening new avenues for therapeutic intervention. Relay’s pipeline comprises multiple preclinical and clinical programs aimed at oncogenic drivers implicated in a range of solid tumors. Relay Therapeutics has progressed a number of assets into human trials, with initial studies evaluating safety, tolerability and preliminary signs of clinical activity. In addition to its internal development programs, the company collaborates with academic institutions and other biopharmaceutical companies to expand the application of its platform across diverse therapeutic areas. Relay’s research efforts are supported by partnerships that bring complementary expertise and resources to accelerate the identification of novel drug candidates. Under the leadership of President and Chief Executive Officer Michael Gilman, Ph.D., Relay Therapeutics continues to advance its vision of precision oncology medicines that address unmet medical needs. The company’s operations are primarily based in the United States, while its clinical trials enroll patients across North America and select international sites. Relay Therapeutics is publicly traded on the Nasdaq under the ticker symbol RLAY.View Relay Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
